Armata Pharmaceuticals, Inc.
ARMP
$9.00
$0.182.04%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.22% | -7.55% | 84.67% | 0.00% | 14.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.22% | -7.55% | 84.67% | 0.00% | 14.24% |
| Cost of Revenue | -46.91% | -55.46% | -37.59% | -52.49% | -47.07% |
| Gross Profit | 63.89% | 68.37% | 59.74% | 61.47% | 56.56% |
| SG&A Expenses | -5.44% | 58.79% | 55.76% | 76.23% | 85.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.12% | -18.19% | -7.82% | 1.41% | 4.83% |
| Operating Income | 26.43% | 19.59% | 15.99% | -1.58% | -3.78% |
| Income Before Tax | -818.79% | -13.39% | 61.66% | 99.46% | 72.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -818.79% | -13.39% | 61.66% | 99.46% | 72.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -818.79% | -13.39% | 61.66% | 99.46% | 72.60% |
| EBIT | 26.43% | 19.59% | 15.99% | -1.58% | -3.78% |
| EBITDA | 27.78% | 20.83% | 17.15% | -0.78% | -2.99% |
| EPS Basic | -813.94% | -13.07% | 61.76% | 99.47% | 72.63% |
| Normalized Basic EPS | 9.82% | 3.65% | 1.16% | -18.40% | -20.79% |
| EPS Diluted | -197.55% | -16.24% | 43.78% | 50.76% | 18.60% |
| Normalized Diluted EPS | -2.46% | 14.10% | 11.51% | 9.29% | -4.36% |
| Average Basic Shares Outstanding | 0.22% | 0.16% | 0.19% | 0.22% | 0.24% |
| Average Diluted Shares Outstanding | -11.28% | 14.60% | 14.63% | 29.19% | 15.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |